Advertisements



Synthetic Cannabinoid Drug Maker Zynerba Plummets 50%

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares retreated to their lowest level since early April following a clinical readout from the company. read more.....»»

Category: blogSource: benzingaJun 30th, 2020

Cannabis Watch: Marijuana-derived epilepsy-drug sales rise 25%, but GW Pharma stock plunges more than 12%

Shares of GW Pharmaceuticals PLC sunk more than 12% in the extended session Tuesday, after the cannabinoid drug maker reported better-than-expected revenue from its flagship product, Epidiolex......»»

Category: topSource: marketwatchNov 5th, 2019

"Renewed Sense Of Hope": GW Pharma CEO Talks Epilepsy Drug Approval In Europe

Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "histori read more.....»»

Category: blogSource: benzingaSep 25th, 2019

"We"re ahead of the pack" in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus

Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis......»»

Category: topSource: madmoneySep 20th, 2018

As it seeks prostate cancer drug approval, Peninsula drug maker targets a forgotten market: Black men

A coalition works increase diversity in research and create a digital resource for men with prostate cancer......»»

Category: topSource: bizjournalsJul 6th, 2020

Zynerba plummets 51% after its CBD gel fails trial for rare disease (ZYNE)

Zynerba, a small biotechnology company, plummeted 51% on Tuesday after its CBD gel failed a pivotal trial for a rare disorder called Fragile X syndrome. The company said its.....»»

Category: smallbizSource: nytJun 30th, 2020

Johnson & Johnson accelerates initiation of human trial of COVID-19 virus vaccine

Shares of Johnson & Johnson rallied 1.3% in morning trading Wednesday, after the drug maker said it has accelerated the initiation of the phase 1/2a first-in-human clinical trial of Ad26.COV2-S, which is its investigational SARS-CoV-2 v.....»»

Category: topSource: marketwatchJun 10th, 2020

Novus Therapeutics stock loses nearly half its value after disappointing drug trial results

Shares of Novus Therapeutics Inc. lost nearly half their value in active trading Monday, after the specialty drug maker announced disa.....»»

Category: topSource: marketwatchJun 1st, 2020

Asia Markets: Asian markets gain on new hope for coronavirus vaccine

Asian markets rose in early trading Tuesday, following sharp gains on Wall Street as the U.S. economy continued to slowly reopen and drug maker Moderna announced positive early results from a potential COVID-19 vaccine......»»

Category: topSource: marketwatchMay 19th, 2020

Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

DEVON, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.....»»

Category: earningsSource: benzingaMay 11th, 2020

Bausch Health"s stock drops after a surprise decline in revenue and lowered outlook

Shares of Bausch Health Companies Inc. sank 3.6% in premarket trading Thursday, after the drug and medical-device products maker reported a wider net loss and a surprise decline in revenue given the negative effects of the COVID-19 pandemic. T.....»»

Category: topSource: marketwatchMay 7th, 2020

Gilead looking for drug-maker partners for its coronavirus experimental drug

Gilead Sciences Inc. said late Tuesday it was "in discussions" with unnamed chemic.....»»

Category: topSource: marketwatchMay 5th, 2020

Gilead to work with partners to ramp up production of potential coronavirus treatment

Gilead Sciences Inc, maker of the experimental coronavirus drug remdesivir, on Thursday said it will work with international partners to expand production of the potential COVID-19 treatment......»»

Category: topSource: reutersApr 30th, 2020

Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-quarter results

Gilead Sciences Inc , maker of the experimental coronavirus drug remdesivir, on Thursday said it will work with international partners to expand production of the potential COVID-19 treatment......»»

Category: topSource: reutersApr 30th, 2020

Amgen stock ticks higher after earnings beat

Amgen Inc. shares advanced in the extended session Thursday after the biotech drug maker topped Wall Street estimates for the quarter. Amgen shares rose 2% after hours, following a 1.5% gain in the .....»»

Category: topSource: marketwatchApr 30th, 2020

Gilead aims to expand remdesivir output for COVID-19, posts flat first-quarter results

Gilead Sciences Inc , maker of the experimental coronavirus drug remdesivir, on Thursday reported flat first-quarter earnings and said it with work with international partners to expand production of potential COVID-19 treatment......»»

Category: topSource: reutersApr 30th, 2020

NewsWatch: S&P 500 climbs above 2,900 as drug maker Gilead says trial for coronavirus treatment has met initial goal

Stocks traded sharply higher Wednesday as reports that a drugmaker’s clinical trial for a treatment to help patients recover more quickly from the COVID-19 disease helped to offset a plunge in U.S. first-quarter gross domestic product.......»»

Category: topSource: marketwatchApr 29th, 2020

Market Snapshot: Dow surges more than 350 points as drug maker Gilead says trial for coronavirus treatment has met initial goal

Stocks traded sharply higher early Wednesday as reports that a drugmaker’s clinical trial for a treatment to help patients recover more quickly from the COVID-19 disease helped to offset a plunge in U.S. first-quarter gross domestic product.......»»

Category: topSource: marketwatchApr 29th, 2020

Dow Jones Newswires: Roche developing coronavirus serology test

The Swiss drug maker said the Elecsys Anti-Sars-CoV-2 immunoassay is an in-vitro test to detect antibodies and assess the body’s immune reaction to Sars-CoV-2, better known as Covid-19, using human serum and plasma from a blood sample......»»

Category: topSource: marketwatchApr 17th, 2020

Tylenol, Zyrtec sales boost J&J"s profit

The coronavirus crisis drove Johnson & Johnson's quarterly profit higher as consumers stocked up on its over-the-counter drugs. But as Fred Katayama reports, the drug maker lowered its full-year earnings forecast......»»

Category: videoSource: reutersApr 14th, 2020

Trump’s personal stake in the malaria-drug maker Sanofi could be as small as $99

The New York Times, in a major article, says Trump has a “small personal stake” in Sanofi, the French drugmaker that produces the drug. Here’s how small......»»

Category: topSource: marketwatchApr 7th, 2020